The effect of botulinum toxin A in children with non-neurogenic therapy-refractory dysfunctional voiding - A systematic review.
Abstract
[INTRODUCTION] Dysfunctional voiding (DV) is a habitual voiding disorder caused by involuntary contraction or non-relaxation of the external urethral sphincter (EUS) during voiding. This contraction causes high post-void residuals (PVR), urinary incontinence and urinary tract infections (UTIs). Various treatments for DV are available, but some children do not respond. Intersphincteric botulinum toxin-A (BTX-A) may be a possible treatment for therapy-refractory children with DV.
[OBJECTIVE] The aim of this systematic review is to summarize the effects and safety of intersphincteric BTX-A as a treatment for therapy-refractory DV in children.
[METHODS] A systematic search in Embase, MEDLINE, Cochrane, and Web of Science databases was performed. Studies reporting on the usage of intersphincteric BTX-A as a treatment for DV in children were included. Data on PVR, maximum flow rate (Qmax), repeat injections and complications were extracted.
[RESULTS] From a total of 277 articles, five cohort studies were identified, reporting on 78 children with DV of whom 53 were female (68 %) and 25 were male (32 %). Sample sizes ranged from ten to twenty patients. Mean or median age at the time of intervention ranged from 8 to 10.5 years. Meta-analysis could not be performed due to lack of data. The narrative synthesis approach was therefore used to summarize the results. All studies showed significant decrease in PVR after BTX-A injection. Three studies showed a 33-69 % improvement on incontinence after BTX-A injection. Less UTIs were reported after treatment. A temporary increase in incontinence, UTIs and transitory numbness to the gluteus muscle were reported as side-effects.
[CONCLUSIONS] BTX-A could be a safe and effective treatment option for therapy-refractory DV in children by reducing PVR, UTIs and incontinence. Hereby, the synergistic effect of BTX-A and urotherapy should be emphasized in future management. Furthermore, this study identified gaps in current knowledge that are of interest for future research.
[OBJECTIVE] The aim of this systematic review is to summarize the effects and safety of intersphincteric BTX-A as a treatment for therapy-refractory DV in children.
[METHODS] A systematic search in Embase, MEDLINE, Cochrane, and Web of Science databases was performed. Studies reporting on the usage of intersphincteric BTX-A as a treatment for DV in children were included. Data on PVR, maximum flow rate (Qmax), repeat injections and complications were extracted.
[RESULTS] From a total of 277 articles, five cohort studies were identified, reporting on 78 children with DV of whom 53 were female (68 %) and 25 were male (32 %). Sample sizes ranged from ten to twenty patients. Mean or median age at the time of intervention ranged from 8 to 10.5 years. Meta-analysis could not be performed due to lack of data. The narrative synthesis approach was therefore used to summarize the results. All studies showed significant decrease in PVR after BTX-A injection. Three studies showed a 33-69 % improvement on incontinence after BTX-A injection. Less UTIs were reported after treatment. A temporary increase in incontinence, UTIs and transitory numbness to the gluteus muscle were reported as side-effects.
[CONCLUSIONS] BTX-A could be a safe and effective treatment option for therapy-refractory DV in children by reducing PVR, UTIs and incontinence. Hereby, the synergistic effect of BTX-A and urotherapy should be emphasized in future management. Furthermore, this study identified gaps in current knowledge that are of interest for future research.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | urinary tract
|
scispacy | 1 | ||
| 해부 | urinary
|
scispacy | 1 | ||
| 합병증 | voiding -
|
scispacy | 1 | ||
| 합병증 | urethral sphincter
|
scispacy | 1 | ||
| 약물 | UTIs
→ urinary tract infections
|
scispacy | 1 | ||
| 약물 | BTX-A
→ botulinum toxin-A
|
scispacy | 1 | ||
| 약물 | [OBJECTIVE]
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] BTX-A
|
scispacy | 1 | ||
| 약물 | botulinum toxin A
|
C0006050
botulinum toxin type A
|
scispacy | 1 | |
| 약물 | [INTRODUCTION] Dysfunctional voiding
|
scispacy | 1 | ||
| 질환 | gluteus muscle
|
scispacy | 1 | ||
| 질환 | habitual voiding disorder
|
scispacy | 1 | ||
| 질환 | urinary incontinence
|
C0042024
Urinary Incontinence
|
scispacy | 1 | |
| 질환 | urinary tract infections
|
C0042029
Urinary tract infection
|
scispacy | 1 | |
| 질환 | UTIs
→ urinary tract infections
|
C0042029
Urinary tract infection
|
scispacy | 1 | |
| 질환 | incontinence
|
C0021167
Incontinence
|
scispacy | 1 | |
| 질환 | numbness
|
C0020580
Hypesthesia
|
scispacy | 1 | |
| 기타 | botulinum toxin-A
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | PVR
→ post-void residuals
|
scispacy | 1 | ||
| 기타 | botulinum toxin A
|
scispacy | 1 | ||
| 기타 | children
|
scispacy | 1 |
MeSH Terms
Humans; Botulinum Toxins, Type A; Child; Urination Disorders; Neuromuscular Agents; Treatment Outcome
📑 인용 관계
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.